Translating slow-binding inhibition kinetics into cellular and in vivo effects.

Many drug candidates fail in clinical trials owing to a lack of efficacy from limited target engagement or an insufficient therapeutic index. Minimizing off-target effects while retaining the desired pharmacodynamic (PD) response can be achieved by reduced exposure for drugs that display kinetic selectivity in which the drug-target complex has a longer half-life than off-target-drug complexes. However, though slow-binding inhibition kinetics are a key feature of many marketed drugs, prospective tools that integrate drug-target residence time into predictions of drug efficacy are lacking, hindering the integration of drug-target kinetics into the drug discovery cascade. Here we describe a mechanistic PD model that includes drug-target kinetic parameters, including the on- and off-rates for the formation and breakdown of the drug-target complex. We demonstrate the utility of this model by using it to predict dose response curves for inhibitors of the LpxC enzyme from Pseudomonas aeruginosa in an animal model of infection.

[1]  D. Mager,et al.  Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic models , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[2]  Robert A Copeland,et al.  Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. , 2005, Methods of biochemical analysis.

[3]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[4]  Michael Nikolaou,et al.  Modeling of Microbial Population Responses to Time-Periodic Concentrations of Antimicrobial Agents , 2007, Annals of Biomedical Engineering.

[5]  J. Walker,et al.  Mechanisms Decreasing In Vitro Susceptibility to the LpxC Inhibitor CHIR-090 in the Gram-Negative Pathogen Pseudomonas aeruginosa , 2011, Antimicrobial Agents and Chemotherapy.

[6]  Robert A Copeland,et al.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. , 2013, Blood.

[7]  Mark E Bunnage,et al.  Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. , 2011, Journal of medicinal chemistry.

[8]  M. Pirrung,et al.  Molecular Validation of LpxC as an Antibacterial Drug Target in Pseudomonas aeruginosa , 2006, Antimicrobial Agents and Chemotherapy.

[9]  Paul Morgan,et al.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.

[10]  ウィッタカー，マーク,et al.  Hydroxamic acid derivatives as antibacterial agents , 1999 .

[11]  D. Mager.  Target-mediated drug disposition and dynamics. , 2006, Biochemical pharmacology.

[12]  J. Rabinowitz,et al.  Absolute Metabolite Concentrations and Implied Enzyme Active Site Occupancy in Escherichia coli , 2009, Nature chemical biology.

[13]  D. Swinney.  The role of binding kinetics in therapeutically useful drug action. , 2009, Current opinion in drug discovery & development.

[14]  N. Masuda,et al.  Substrate Specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM Efflux Pumps in Pseudomonas aeruginosa , 2000, Antimicrobial Agents and Chemotherapy.

[15]  Nathanael S Gray,et al.  Developing irreversible inhibitors of the protein kinase cysteinome. , 2013, Chemistry & biology.

[16]  Pei Zhou,et al.  Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis. , 2008, Current pharmaceutical biotechnology.

[17]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[18]  J F Morrison,et al.  Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. , 1969, Biochimica et biophysica acta.

[19]  Robert A Copeland,et al.  The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety , 2010, Expert opinion on drug discovery.

[20]  Cathrine A. McKenzie.  Antibiotic dosing in critical illness. , 2011, The Journal of antimicrobial chemotherapy.

[21]  G. Vauquelin.  Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time , 2010, Expert opinion on drug discovery.

[22]  I. Kariv,et al.  Development of a high throughput equilibrium dialysis method. , 2001, Journal of pharmaceutical sciences.

[23]  H. Nikaido,et al.  Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples , 1993, Antimicrobial Agents and Chemotherapy.

[24]  W. Craig,et al.  Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. , 1983, The Journal of infectious diseases.

[25]  V. Shanmugasundaram,et al.  Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. , 2012, Journal of medicinal chemistry.

[26]  T. Cheng,et al.  Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[27]  R. Copeland,et al.  Residence time of receptor-ligand complexes and its effect on biological function. , 2008, Biochemistry.

[28]  J F Morrison,et al.  The kinetics of reversible tight-binding inhibition. , 1979, Methods in enzymology.

[29]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[30]  George L. Drusano,et al.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.

[31]  P. Miller,et al.  Bacterial uptake of aminoglycoside antibiotics. , 1987, Microbiological reviews.

[32]  R. Copeland,et al.  Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis. , 2011, Analytical biochemistry.

[33]  L. Valera,et al.  Comparative Killing Rates of Fluoroquinolones and Cell Wall-Active Agents , 2000, Antimicrobial Agents and Chemotherapy.

[34]  Frieder Keller,et al.  Mechanism-based pharmacokinetic–pharmacodynamic modeling of antimicrobial drug effects , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[35]  J. Arrowsmith.  Trial watch: Phase II failures: 2008–2010 , 2011, Nature Reviews Drug Discovery.

[36]  S. Bajaksouzian,et al.  Postantibiotic Effects of Grepafloxacin Compared to Those of Five Other Agents against 12 Gram-Positive and -Negative Bacteria , 2000, Antimicrobial Agents and Chemotherapy.

[37]  H. Smith,et al.  Pathogenicity and the microbe in vivo. The 1989 Fred Griffith Review Lecture. , 1990, Journal of general microbiology.

[38]  J. DiMasi,et al.  Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs , 2010, Clinical pharmacology and therapeutics.

[39]  J. Morrison,et al.  [17] The kinetics of reversible tight-binding inhibition , 1979 .

[40]  Matthew D. Miller,et al.  Exploring the UDP pocket of LpxC through amino acid analogs. , 2013, Bioorganic & medicinal chemistry letters.

[41]  H. Schweizer,et al.  Construction of improved Escherichia-Pseudomonas shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in Pseudomonas aeruginosa. , 1994, Gene.

[42]  W. Craig,et al.  The in-vivo postantibiotic effect of imipenem and other new antimicrobials. , 1986, The Journal of antimicrobial chemotherapy.

[43]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[44]  D. Swinney,et al.  Biochemical Mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001‐2004: Mechanisms leading to optimal efficacy and safety. , 2006, Current topics in medicinal chemistry.

[45]  H. Ni,et al.  Discovery of Inhibitors of 4′-Phosphopantetheine Adenylyltransferase (PPAT) To Validate PPAT as a Target for Antibacterial Therapy , 2013, Antimicrobial Agents and Chemotherapy.

[46]  H. Schweizer,et al.  A 10-min method for preparation of highly electrocompetent Pseudomonas aeruginosa cells: application for DNA fragment transfer between chromosomes and plasmid transformation. , 2006, Journal of microbiological methods.

[47]  C. Walsh,et al.  The behavior and significance of slow-binding enzyme inhibitors. , 2006, Advances in enzymology and related areas of molecular biology.

[48]  W. Windsor,et al.  In vitro kinetic profiling of hepatitis C virus NS3 protease inhibitors by progress curve analysis. , 2013, Methods in molecular biology.

[49]  D. Christianson,et al.  Binding of uridine 5'-diphosphate in the "basic patch" of the zinc deacetylase LpxC and implications for substrate binding. , 2006, Biochemistry.

[50]  W. Craig,et al.  Postantibiotic suppression of bacterial growth. , 1981, Reviews of infectious diseases.

[51]  Peter J. Tonge,et al.  Rational optimization of drug-target residence time: insights from inhibitor binding to the Staphylococcus aureus FabI enzyme-product complex. , 2013, Biochemistry.

[52]  William J Jusko,et al.  Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[53]  S. McLeod,et al.  Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain. , 2014, Protein expression and purification.

[54]  P. Tonge,et al.  Drug-target residence time: critical information for lead optimization. , 2010, Current opinion in chemical biology.

[55]  C. Fierke,et al.  Mechanistic inferences from the binding of ligands to LpxC, a metal-dependent deacetylase. , 2006, Biochemistry.

[56]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.